Alchemab Therapeutics raises $34M
Alchemab Therapeutics announced a Series A round of $34M on 8 July 2026. The company operates in HealthTech and is based in United Kingdom. It was founded by Jane Osbourn, CEO & Co-founder.
Founder
Jane Osbourn
CEO & Co-founder, Alchemab Therapeutics
Outreach angles
- -Jane Osbourn OBE was a senior leader at MedImmune following AstraZeneca's acquisition of Cambridge Antibody Technology.
- -She co-founded Alchemab to discover protective antibodies from disease-resilient individuals and made The Power List 2024.
- -The €29.3M Series A extension from the British Business Bank funds Alchemab's ALS antibody ATLX-1282 and dataset expansion.
Signals
Series AHealthcareDeep TechAI-NativeB2BHiring
Round details
Company: Alchemab Therapeutics
Domain: alchemab.com
Amount: $34M
Stage: Series A
Industry: HealthTech
Country: United Kingdom
Announced: 8 July 2026
Other HealthTech raises
Recently funded in United Kingdom